(Q34082750)

30 July 2017

1 reference

title

Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole (English)

1 reference

30 July 2017

1 reference

A B Thomson

1

1 reference

30 July 2017

1 December 2000

1 reference

Current gastroenterology reports

30 July 2017

1 reference

30 July 2017

2

1 reference

30 July 2017

482-493

1 reference

30 July 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s11894-000-0013-0

30 July 2017

0 references

cites work

Treatment after failure: the problem of "non-responders".

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11894-000-0013-0

A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial

21 January 2018

1 reference

12 December 2020

Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis

1 reference

12 December 2020

Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion

1 reference

12 December 2020

Pantoprazole versus omeprazole in the treatment of acute gastric ulcers.

1 reference

12 December 2020

Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer

1 reference

12 December 2020

Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.

1 reference

12 December 2020

Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group

1 reference

12 December 2020

Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group

1 reference

12 December 2020

[Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence]

1 reference

12 December 2020

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

12 December 2020

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

1 reference

12 December 2020

Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study.

1 reference

12 December 2020

Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial

1 reference

12 December 2020

Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group

1 reference

12 December 2020

Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicentre study

1 reference

12 December 2020

Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population

1 reference

12 December 2020

Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression

1 reference

12 December 2020

Review article: drug interactions with agents used to treat acid-related diseases

1 reference

12 December 2020

Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study

1 reference

12 December 2020

Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group

1 reference

12 December 2020

A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis

1 reference

12 December 2020

Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial

1 reference

12 December 2020

One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group

1 reference

12 December 2020

Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease

1 reference

12 December 2020

Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study

1 reference

12 December 2020

Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial

1 reference

12 December 2020

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease

1 reference

12 December 2020

Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group

1 reference

12 December 2020

Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study

1 reference

12 December 2020

One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients

1 reference

12 December 2020

Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole

1 reference

12 December 2020

Comparison of lansoprazole and omeprazole in the short-term management of duodenal ulcers in Taiwan

1 reference

12 December 2020

Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects

1 reference

12 December 2020

Eradication of Helicobacter pylori: an objective assessment of current therapies

1 reference

12 December 2020

Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs

1 reference

12 December 2020

Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders

1 reference

12 December 2020

Rapid healing of gastric ulcers with lansoprazole

1 reference

12 December 2020

Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies).

1 reference

12 December 2020

Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection

1 reference

12 December 2020

Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders

1 reference

12 December 2020

10.1007/S11894-000-0013-0

Identifiers

DOI

1 reference

PubMed ID

11079051

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

11079051